351 related articles for article (PubMed ID: 27221627)
1. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
Savitz J
Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
[TBL] [Abstract][Full Text] [Related]
2. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
[TBL] [Abstract][Full Text] [Related]
3. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
4. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
5. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
[TBL] [Abstract][Full Text] [Related]
6. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse.
Saito K; Markey SP; Heyes MP
Neuroscience; 1992 Nov; 51(1):25-39. PubMed ID: 1465184
[TBL] [Abstract][Full Text] [Related]
7. Phase-and disorder-specific differences in peripheral metabolites of the kynurenine pathway in major depression, bipolar affective disorder and schizophrenia.
Brum M; Nieberler M; Kehrwald C; Knopf K; Brunkhorst-Kanaan N; Etyemez S; Allers KA; Bittner RA; Slattery DA; McNeill RV; Reif A; Kittel-Schneider S
World J Biol Psychiatry; 2023; 24(7):564-577. PubMed ID: 36648064
[TBL] [Abstract][Full Text] [Related]
8. MM165 - A Small Hybrid Molecule Modulates the Kynurenine Pathway and Attenuates Lipopolysaccharide-Induced Memory Deficits and Inflammation.
Kotańska M; Łanocha M; Bednarski M; Marcinkowska M
Neurochem Res; 2024 May; 49(5):1200-1211. PubMed ID: 38381245
[TBL] [Abstract][Full Text] [Related]
9. Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies.
Arnone D; Saraykar S; Salem H; Teixeira AL; Dantzer R; Selvaraj S
Neurosci Biobehav Rev; 2018 Sep; 92():477-485. PubMed ID: 29940237
[TBL] [Abstract][Full Text] [Related]
10. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
Laugeray A; Launay JM; Callebert J; Surget A; Belzung C; Barone PR
Behav Brain Res; 2010 Jun; 210(1):84-91. PubMed ID: 20153778
[TBL] [Abstract][Full Text] [Related]
11. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Savitz J; Drevets WC; Smith CM; Victor TA; Wurfel BE; Bellgowan PS; Bodurka J; Teague TK; Dantzer R
Neuropsychopharmacology; 2015 Jan; 40(2):463-71. PubMed ID: 25074636
[TBL] [Abstract][Full Text] [Related]
12. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression.
Miura H; Ozaki N; Sawada M; Isobe K; Ohta T; Nagatsu T
Stress; 2008 May; 11(3):198-209. PubMed ID: 18465467
[TBL] [Abstract][Full Text] [Related]
13. Targeting the kynurenine pathway as a potential strategy to prevent and treat Alzheimer's disease.
Gong CY; Li Z; Wang HM; Liu J; Chen L; Zhang HW; Wang X; Yang J
Med Hypotheses; 2011 Sep; 77(3):383-5. PubMed ID: 21683531
[TBL] [Abstract][Full Text] [Related]
14. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.
Bay-Richter C; Linderholm KR; Lim CK; Samuelsson M; Träskman-Bendz L; Guillemin GJ; Erhardt S; Brundin L
Brain Behav Immun; 2015 Jan; 43():110-7. PubMed ID: 25124710
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Savitz J; Dantzer R; Wurfel BE; Victor TA; Ford BN; Bodurka J; Bellgowan PS; Teague TK; Drevets WC
Psychoneuroendocrinology; 2015 Feb; 52():200-11. PubMed ID: 25486577
[TBL] [Abstract][Full Text] [Related]
16. [Kynurenine and its metabolites in nervous system diseases].
Vécsei L; Schwab F
Orv Hetil; 1992 Jul; 133(29):1803-7. PubMed ID: 1386152
[TBL] [Abstract][Full Text] [Related]
17. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
[TBL] [Abstract][Full Text] [Related]
18. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?
Quak J; Doornbos B; Roest AM; Duivis HE; Vogelzangs N; Nolen WA; Penninx BW; Kema IP; de Jonge P
Psychoneuroendocrinology; 2014 Jul; 45():202-10. PubMed ID: 24845191
[TBL] [Abstract][Full Text] [Related]
19. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.
Réus GZ; Jansen K; Titus S; Carvalho AF; Gabbay V; Quevedo J
J Psychiatr Res; 2015 Sep; 68():316-28. PubMed ID: 26028548
[TBL] [Abstract][Full Text] [Related]
20. Kynurenines: from the perspective of major psychiatric disorders.
Myint AM
FEBS J; 2012 Apr; 279(8):1375-85. PubMed ID: 22404766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
